The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Perspective
Volume 350:2327-2329 June 3, 2004 Number 23
NextNext

Waiting for Plan B — The FDA and Nonprescription Use of Emergency Contraception
Robert Steinbrook, M.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Commentary
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
The proposal to switch levonorgestrel emergency contraception (sold under the brand name Plan B) to over-the-counter status in the United States is in limbo. In May, the Food and Drug Administration (FDA) rejected the application of Barr Pharmaceuticals for nonprescription sales of Plan B. Dr. Steven Galson, the acting director of the FDA's Center for Drug Evaluation and Research, wrote that the company had "not provided adequate data to support a conclusion that Plan B can be used safely by young adolescent women for emergency contraception without the professional supervision of a practitioner licensed by law to administer the drug." . . . [Full Text of this Article]


Related Letters:

Plan B — The FDA and Emergency Contraception
Schwarz E. B.
Extract | Full Text | PDF  
N Engl J Med 2004; 351:1031-1032, Sep 2, 2004. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.